Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome

Molecular Brain

Volumn 6, Issue 1, 2013, Pages

  Szemes, Marianna ^a   Davies, Rachel L ^a   Garden, Claire L P ^b   Usowicz, Maria M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

Author keywords

Cerebellum; Down syndrome; Down's syndrome; GABA A receptor; Granule cell; qPCR; Shunting; Single cell RT PCR; Tonic inhibition; Ts65Dn

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; RECEPTOR SUBUNIT; SYNAPSE RECEPTOR; MESSENGER RNA; PROTEIN SUBUNIT;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DOWN SYNDROME; EXON; FEMALE; GABAERGIC TRANSMISSION; GENETIC VARIABILITY; GRANULE CELL; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN QUATERNARY STRUCTURE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VOLTAGE CLAMP; WILD TYPE; ANIMAL; C57BL MOUSE; CHANNEL GATING; DISEASE MODEL; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN SUBUNIT; TRANSGENIC MOUSE;

MUS;

ACTION POTENTIALS; ANIMALS; CEREBELLUM; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ELECTROPHYSIOLOGICAL PHENOMENA; GENE EXPRESSION REGULATION; HUMANS; ION CHANNEL GATING; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN SUBUNITS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GABA-A; RNA, MESSENGER;

EID: 84880334370     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-6-33     Document Type: Article

References (124)

1. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Khoshnood B, Greenlees R, Loane M, Dolk H, on behalf of the EUROCAT Project Management Committee, Birth Defects Res A Clin Mol Teratol 2011 91 16 S22 10.1002/bdra.20776 21381186
2. Pathways to cognitive deficits in Down syndrome. Sturgeon X, Le T, Ahmed MM, Gardiner KJ, Prog Brain Res 2012 197 73 100 22541289
3. Genomic determinants in the phenotypic variability of Down syndrome. Letourneau A, Antonarakis SE, Prog Brain Res 2012 197 15 28 22541286
4. Neurological phenotypes for Down syndrome across the life span. Lott IT, Prog Brain Res 2012 197 101 121 22541290
5. Human and mouse model cognitive phenotypes in Down syndrome: implications for assessment. Edgin JO, Mason GM, Spano G, Fernandez A, Nadel L, Prog Brain Res 2012 197 123 151 22541291
6. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. Vilardell M, Rasche A, Thormann A, Maschke-Dutz E, Perez-Jurado LA, Lehrach H, Herwig R, BMC Genomics 2011 12 229 10.1186/1471-2164-12-229 21569303
7. Alterations of brain circuits in Down syndrome murine models. Gotti S, Caricati E, Panzica G, J Chem Neuroanat 2011 42 317 326 10.1016/j.jchemneu.2011. 09.002 21946025
8. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC, J Neurosci 2004 24 8153 8160 10.1523/JNEUROSCI.1766-04.2004 15371516 (Pubitemid 39280835)
9. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome. Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z, Neuropharmacology 1997 36 1549 1554 10.1016/S0028-3908(97)00157-3 9517425 (Pubitemid 28085914)
10. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z, Neuropharmacology 1999 38 1917 1920 10.1016/S0028-3908(99)00083-0 10608287 (Pubitemid 29509730)
11. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, Garner CC, Nat Neurosci 2007 10 411 413 17322876 (Pubitemid 46494581)
12. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Costa ACS, Grybko MJ, Neurosci Lett 2005 382 317 322 10.1016/j.neulet.2005.03.031 15925111 (Pubitemid 40733644)
13. Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome. Best TK, Cramer NP, Chakrabarti L, Haydar TF, Galdzicki Z, Exp Neurol 2012 233 749 757 10.1016/j.expneurol.2011.11.033 22178330
14. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT, Salehi A, Mobley WC, Neurobiol Dis 2012 45 683 691 10.1016/j.nbd.2011.10.009 22062771
15. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC, J Neurosci 2012 32 9217 9227 10.1523/JNEUROSCI.1673-12.2012 22764230
16. Discoveries in Down syndrome: moving basic science to clinical care. Kleschevnikov AM, Belichenko PV, Salehi A, Wu C, Prog Brain Res 2012 197 199 221 22541294
17. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Rueda N, Florez J, Martinez-Cue C, Neural Plast 2012 2012 584071 22685678
18. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Chakrabarti L, Best TK, Cramer NP, Carney RSE, Isaac JTR, Galdzicki Z, Haydar TF, Nat Neurosci 2010 13 927 934 10.1038/nn.2600 20639873
19. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Cramer N, Galdzicki Z, Neural Plast 2012 2012 101542 22848844
20. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Galante M, Jani H, Vanes L, Daniel H, Fisher EMC, Tybulewicz VLJ, Bliss TVP, Morice E, Hum Mol Genet 2009 18 1449 1463 10.1093/hmg/ddp055 19181682
21. Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome. Usowicz MM, Garden CLP, Brain Res 2012 1465 10 17 22627164
22. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, Gunning FM, McQuain JD, Driesen NR, Acker JD, Neurol 1995 45 356 366 10.1212/WNL.45.2.356
23. Cerebellar volume in adults with Down syndrome. Aylward EH, Habbak R, Warren AC, Pulsifer MB, Barta PE, Jerram M, Pearlson GD, Arch Neurol 1997 54 209 212 10.1001/archneur.1997.00550140077016 9041863 (Pubitemid 27078729)
24. Anomalous brain morphology on magnetic resonance images in Williams syndrome and Down syndrome. Jernigan TL, Bellugi U, Arch Neurol 1990 47 529 533 10.1001/archneur.1990.00530050049011 2139774 (Pubitemid 20155841)
25. Neuroanatomy of Down's syndrome: a high-resolution MRI study. Pinter JD, Eliez S, Schmitt JE, Capone GT, Reiss AL, Am J Psychiatry 2001 158 1659 1665 10.1176/appi.ajp.158.10.1659 11578999 (Pubitemid 32923659)
26. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Baxter LL, Moran TH, Richtsmeier JT, Troncoso J, Reeves RH, Hum Mol Genet 2000 9 195 202 10.1093/hmg/9.2.195 10607830 (Pubitemid 30052743)
27. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Guidi S, Ciani E, Bonasoni P, Santini D, Bartesaghi R, Brain Pathol 2011 21 361 373 10.1111/j.1750-3639.2010.00459.x 21040072
28. Trisomy 21 and early brain development. Haydar TF, Reeves RH, Trends Neurosci 2011 35 81 91 22169531
29. Functional topography in the human cerebellum: a meta-analysis of neuroimaging studies. Stoodley CJ, Schmahmann JD, Neuroimage 2009 44 489 501 10.1016/j.neuroimage.2008.08.039 18835452
30. The cerebellum and cognition: evidence from functional imaging studies. Stoodley C, Cerebellum 2011 11 1 14
31. Sensory representations in cerebellar granule cells. Arenz A, Bracey EF, Margrie TW, Curr Opin Neurobiol 2009 19 445 451 10.1016/j.conb.2009.07.003 19651506
32. Development of action potential-dependent and independent spontaneous GABAA receptor-mediated currents in granule cells of postnatal rat cerebellum. Wall MJ, Usowicz MM, Eur J Neurosci 1997 9 533 548 10.1111/j.1460-9568.1997. tb01630.x 9104595 (Pubitemid 27144022)
33. Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors. Brickley SG, Cull-Candy SG, Farrant M, J Physiol 1996 497 753 759 9003560
34. Pharmacological and functional implications of developmentally-regulated changes in GABAA receptor subunit expression in the cerebellum. Carlson BX, Elster L, Schousboe A, Eur J Pharmacol 1998 352 1 14 10.1016/S0014-2999(98) 00355-0 9718261 (Pubitemid 28359401)
35. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Brickley SG, Revilla V, Cull-Candy SG, Wisden W, Farrant M, Nature 2001 409 88 92 10.1038/35051086 11343119 (Pubitemid 32098630)
36. Whole-cell and single-channel currents activated by GABA and glycine in granule cells of the rat cerebellum. Kaneda M, Farrant M, Cull-Candy SG, J Physiol 1995 485 419 435 7545231
37. Tonic and spillover inhibition of granule cells control information flow through cerebellar cortex. Hamann M, Rossi DJ, Attwell D, Neuron 2002 33 625 633 10.1016/S0896-6273(02)00593-7 11856535 (Pubitemid 34188437)
38. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Das I, Reeves RH, Dis Model Mech 2011 4 596 606 10.1242/dmm.007716 21816951
39. Axonal abnormalities in cerebellar Purkinje cells of the Ts65Dn mouse. Necchi D, Lomoio S, Scherini E, Brain Res 2008 1238 181 188 18755166
40. The in vivo Down syndrome genomic library in mouse. Herault Y, Duchon A, Velot E, Marechal D, Brault V, Prog Brain Res 2012 197 169 197 22541293
41. Down syndrome gene dosage imbalance on cerebellum development. Moldrich RX, Dauphinot L, Laffaire J, Rossier J, Potier MC, Prog Neurobiol 2007 82 87 94 10.1016/j.pneurobio.2007.02.006 17408845 (Pubitemid 46829600)
42. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Saran NG, Pletcher MT, Natale JE, Cheng Y, Reeves RH, Hum Mol Genet 2003 12 2013 2019 10.1093/hmg/ddg217 12913072 (Pubitemid 37038810)
43. Contributions of the GABAA receptor α6 subunit to phasic and tonic inhibition revealed by a naturally occurring polymorphism in the a6 gene. Santhakumar V, Hanchar HJ, Wallner M, Olsen RW, Otis TS, J Neurosci 2006 26 3357 3364 10.1523/JNEUROSCI.4799-05.2006 16554486
44. Tonic inhibition enhances fidelity of sensory information transmission in the cerebellar cortex. Duguid I, Branco T, London M, Chadderton P, Haüsser M, J Neurosci 2012 32 11132 11143 10.1523/JNEUROSCI.0460-12.2012 22875944
45. Guide to data acquisition and analysis. Heinemann SH, Single-channel Recording Springer, Sakmann B, Neher E, 2 2009 53 94
46. Outwardly rectifying tonically active GABAA receptors in pyramidal cells modulate neuronal offset, not gain. Pavlov I, Savtchenko LP, Kullmann DM, Semyanov A, Walker MC, J Neurosci 2009 29 15341 15350 10.1523/JNEUROSCI.2747-09. 2009 19955387
47. GABA potency at GABA(A) receptors found in synaptic and extrasynaptic Zones. Mortensen M, Patel B, Smart TG, Front Cell Neurosci 2011 6 1 22319471
48. Extrasynaptic GABAA receptors: their function in the CNS and implications for disease. Brickley S, Mody I, Neuron 2012 73 23 34 10.1016/j.neuron.2011.12. 012 22243744
49. Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABAA receptors. Meera P, Wallner M, Otis TS, J Neurophysiol 2011 106 2057 2064 10.1152/jn.00450.2011 21795619
50. Furosemide interactions with brain GABAA receptors. Korpi ER, Luddens H, Br J Pharmacol 1997 120 741 748 10.1038/sj.bjp.0700922 9138676 (Pubitemid 27122710)
51. Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor. Korpi ER, Kuner T, Seeburg PH, Luddens H, Mol Pharmacol 1995 47 283 289 7870036
52. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit. Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ, Mol Pharmacol 1996 50 670 678 8794909 (Pubitemid 26303601)
53. A receptor subunits in the mouse brain. Hörtnagl H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G, Neuroscience 2013 236 347 372
54. Relative densities of synaptic and extrasynaptic GABAA receptors on cerebellar granule cells as determined by a quantitative immunogold method. Nusser Z, Roberts JD, Baude A, Richards JG, Somogyi P, J Neurosci 1995 15 2948 2960 7722639
55. Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. Nusser Z, Sieghart W, Somogyi P, J Neurosci 1998 18 1693 1703 9464994 (Pubitemid 28103077)
56. A receptors. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I, Proc Natl Acad Sci USA 2003 100 14439 14444 10.1073/pnas.2435457100 14623958 (Pubitemid 37499255)
57. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G, Neuroscience 2000 101 815 850 10.1016/S0306-4522(00)00442-5 11113332
58. A receptor is concentrated in synaptic junctions containing the α1 and β2/3 subunits in hippocampus, cerebellum and globus pallidus. Somogyi P, Fritschy JM, Benke D, Roberts JDB, Sieghart W, Neuropharmacology 1996 35 1425 1444 10.1016/S0028-3908(96)00086-X 9014159 (Pubitemid 27013878)
59. Profound desensitization by ambient GABA limits activation of delta-containing GABAA receptors during spillover. Bright DP, Renzi M, Bartram J, McGee TP, MacKenzie G, Hosie AM, Farrant M, Brickley SG, J Neurosci 2011 31 753 763 10.1523/JNEUROSCI.2996-10.2011 21228184
60. A receptor antagonists increase the proportion of functional high-affinity α6 subunit-containing receptors in granule cells of adult rat cerebellum. Wall MJ, Neuropharmacology 2003 44 56 69 10.1016/S0028-3908(02)00331-3 12559122 (Pubitemid 36135842)
61. Spillover-mediated transmission at inhibitory synapses promoted by high affinity alpha6 subunit GABA(A) receptors and glomerular geometry. Rossi DJ, Hamann M, Neuron 1998 20 783 795 10.1016/S0896-6273(00)81016-8 9581769 (Pubitemid 28199056)
62. A receptor α6 subunit. Tia S, Wang JF, Kotchabhakdi N, Vicini S, J Neurosci 1996 16 3630 3640 8642407
63. 2+ imaging in brain slices. Durand G, Marandi N, Herberger S, Blum R, Konnerth A, Pflugers Arch 2006 451 716 726 10.1007/s00424-005-1514-3 16211366 (Pubitemid 43228055)
64. Transcription goes digital. Lionnet T, Singer RH, EMBO Rep 2012 13 313 321 10.1038/embor.2012.31 22410830
65. - in cerebellar granule cells affects their excitability and vestibulo-ocular learning. Seja P, Schonewille M, Spitzmaul G, Badura A, Klein I, Rudhard Y, Wisden W, Hubner CA, De Zeeuw CI, Jentsch TJ, EMBO J 2012 31 1217 1230 10.1038/emboj.2011.488 22252133
66. CNQX increases GABA-mediated synaptic transmission in the cerebellum by an AMPA/kainate receptor-independent mechanism. Brickley SG, Farrant M, Swanson GT, Cull-Candy SG, Neuropharmacology 2001 41 730 736 10.1016/S0028-3908(01) 00135-6 11640927 (Pubitemid 32972190)
67. Integration of quanta in cerebellar granule cells during sensory processing. Chadderton P, Margrie TW, Haüsser M, Nature 2004 428 856 860 10.1038/nature02442 15103377 (Pubitemid 38529500)
68. Presynaptic GABAA receptors enhance transmission and LTP induction at hippocampal mossy fiber synapses. Ruiz A, Campanac E, Scott RS, Rusakov DA, Kullmann DM, Nat Neurosci 2010 13 431 438 10.1038/nn.2512 20305647
69. Shunting versus inactivation: analysis of presynaptic inhibitory mechanisms in primary afferents of the crayfish. Cattaert D, El Manira A, J Neurosci 1999 19 6079 6089 10407044 (Pubitemid 29327940)
70. Differential effects of axon initial segment and somatodendritic GABAA receptors on excitability measures in rat dentate granule neurons. Rojas P, Akrouh A, Eisenman LN, Mennerick S, J Neurophysiol 2011 105 366 379 10.1152/jn.00165.2010 21068264
71. Shunting versus inactivation: Simulation of GABAergic inhibition in spider mechanoreceptors suggests that either is sufficient. French AS, Panek I, Torkkeli PH, Neurosci Res 2006 55 189 196 10.1016/j.neures.2006.03.002 16616790
72. Properties of putative cerebellar gamma-aminobutyric acid A receptor isoforms. Saxena NC, Macdonald RL, Mol Pharmacol 1996 49 567 579 8643098
73. Diversity of structure and function of alpha1alpha6beta3delta GABAA receptors: comparison with alpha1beta3delta and alpha6beta3delta receptors. Baur R, Kaur KH, Sigel E, J Biol Chem 2010 285 17398 17405 10.1074/jbc.M110.108670 20382738
74. GABAA receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Jacob TC, Moss SJ, Jurd R, Nat Rev Neurosci 2008 9 331 343 10.1038/nrn2370 18382465 (Pubitemid 351556042)
75. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N, Pediatr 2007 120 1465 e1471 10.1542/peds.2006-3448 (Pubitemid 350223666)
76. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Seidl R, Cairns N, Singewald N, Kaehler ST, Lubec G, Naunyn Schmiedebergs Arch Pharmacol 2001 363 139 145 10.1007/s002100000346 11218066 (Pubitemid 32200321)
77. Prenatal NAP + SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and g-aminobutyric acid receptors. Vink J, Incerti M, Toso L, Roberson R, Abebe D, Spong CY, Am J Obstet Gynecol 2009 200 524 19327737
78. A critical period in cortical interneuron neurogenesis in Down syndrome revealed by human neural progenitor cells. Bhattacharyya A, McMillan E, Chen SI, Wallace K, Svendsen CN, Dev Neurosci 2009 31 497 510 10.1159/000236899 19738365
79. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, Mobley WC, J Comp Neurol 2009 512 453 466 10.1002/cne.21895 19034952
80. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. Kuhn DE, Nuovo GJ, Terry AV Jr, Martin MM, Malana GE, Sansom SE, Pleister AP, Beck WD, Head E, Feldman DS, et al. J Biol Chem 2010 285 1529 1543 10.1074/jbc.M109.033407 19897480
81. Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Keck-Wherley J, Grover D, Bhattacharyya S, Xu X, Holman D, Lombardini ED, Verma R, Biswas R, Galdzicki Z, Dev Neurosci 2011 33 451 467 10.1159/000330884 22042248
82. Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. Elton TS, Sansom SE, Martin MM, RNA Biol 2010 7 540 547 10.4161/rna.7.5.12685 21081842
83. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Reinholdt L, Ding Y, Gilbert G, Czechanski A, Solzak J, Roper R, Johnson M, Donahue L, Lutz C, Davisson M, Mamm Genome 2011 22 685 691 10.1007/s00335-011-9357-z 21953412
84. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Duchon A, Raveau M, Chevalier C, Nalesso V, Sharp A, Herault Y, Mamm Genome 2011 22 674 684 10.1007/s00335-011-9356-0 21953411
85. Prediction of both conserved and nonconserved microRNA targets in animals. Wang X, El Naqa IM, Bioinformatics 2008 24 325 332 10.1093/ bioinformatics/btm595 18048393 (Pubitemid 351189007)
86. miRBase: integrating microRNA annotation and deep-sequencing data. Kozomara A, Griffiths-Jones S, Nucl Acids Res 2011 39 152 D157 10.1093/nar/gkq1027 21037258
87. Most mammalian mRNAs are conserved targets of microRNAs. Friedman RC, Farh KK-H, Burge CB, Bartel DP, Genome Res 2009 19 92 105 18955434
88. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Rueda N, Florez J, Martinez-Cue C, Neurosci Lett 2008 433 22 27 10.1016/j.neulet.2007.12.039 18226451
89. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Bartesaghi R, Guidi S, Ciani E, Rev Neurosci 2011 22 419 455 21819263
90. Developmentally altered inhibition in Ts65Dn, a mouse model of Down syndrome. Mitra A, Blank M, Madison DV, Brain Res 2012 1440 1 8 22284618
91. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. Hanson JE, Blank M, Valenzuela RA, Garner CC, Madison DV, J Physiol (Lond) 2007 579 53 67 10.1113/jphysiol. 2006.114868
92. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. Harashima C, Jacobowitz DM, Witta J, Borke RC, Best TK, Siarey RJ, Galdzicki Z, J Comp Neurol 2006 494 815 833 10.1002/cne.20844 16374808 (Pubitemid 43054228)
93. Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down Syndrome mouse model. Harashima C, Jacobowitz D, Stoffel M, Chakrabarti L, Haydar T, Siarey R, Galdzicki Z, Cell Mol Neurobiol 2006 26 1 16 10.1007/s10571-006-8565-7 16633898 (Pubitemid 43987366)
94. Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. Nusser Z, Mody I, J Neurophysiol 2002 87 2624 2628 11976398 (Pubitemid 34670732)
95. GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Semyanov A, Walker MC, Kullmann DM, Nat Neurosci 2003 6 484 490 12679782 (Pubitemid 36514696)
96. A receptor α5 subunit deficient mice. Glykys J, Mody I, J Neurophysiol 2006 95 2796 2807 10.1152/jn.01122.2005 16452257
97. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors. Caraiscos VB, Elliott EM, You-Ten KE, Cheng VY, Belelli D, Newell JG, Jackson MF, Lambert JJ, Rosahl TW, Wafford KA, et al. Proc Natl Acad Sci USA 2004 101 3662 3667 10.1073/pnas.0307231101 14993607 (Pubitemid 38338251)
98. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. Braudeau J, Delatour B, Duchon A, Lopes-Pereira P, Dauphinot L, de Chaumont F, Olivo-Marin JC, Dodd RH, Hérault Y, Potier MC, J Psychopharmacol 2011 25 1030 1042 10.1177/0269881111405366 21693554
99. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome. Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á Flórez J, et al. J Neurosci 2013 33 3953 3966 10.1523/JNEUROSCI.1203-12.2013 23447605
100. Chronic treatment with a promnesiant GABA-A alpha5-selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model. Braudeau J, Dauphinot L, Duchon A, Loistron A, Dodd RH, Herault Y, Delatour B, Potier MC, Adv Pharmacol Sci 2011 2011 153218 22028705
101. Coding with spike shapes and graded potentials in cortical networks. Juusola M, Robinson HP, de Polavieja GG, Bioessays 2007 29 178 187 10.1002/bies.20532 17226812 (Pubitemid 46340252)
102. A comparison of oral structure and oral-motor function in young males with Fragile X syndrome and Down syndrome. Barnes EF, Roberts J, Mirrett P, Sideris J, Misenheimer J, J Speech Lang Hear Res 2006 49 903 917 10.1044/1092-4388(2006/065) 16908884 (Pubitemid 350056563)
103. Cerebellar contributions to speech production and speech perception: psycholinguistic and neurobiological perspectives. Ackermann H, Trends Neurosci 2008 31 265 272 10.1016/j.tins.2008.02.011 18471906
104. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Scattoni ML, Crawley J, Ricceri L, Neurosci Biobehav Rev 2009 33 508 515 10.1016/j.neubiorev.2008.08.003 18771687
105. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, et al. Proc Natl Acad Sci USA 1996 93 13333 13338 10.1073/pnas.93.23.13333 8917591 (Pubitemid 26382816)
106. Motor dysfunction in a mouse model for Down syndrome. Costa AC, Walsh K, Davisson MT, Physiol Behav 1999 68 211 220 10.1016/S0031-9384(99)00178-X 10627083 (Pubitemid 30009803)
107. Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn. Kida E, Rabe A, Walus M, Albertini G, Golabek AA, Exp Neurol 2013 240 178 189 23201095
108. Spontaneous stereotypy in an animal model of Down syndrome: Ts65Dn mice. Turner CA, Presti MF, Newman HA, Bugenhagen P, Crnic L, Lewis MH, Behav Genet 2001 31 393 400 10.1023/A:1012226603255 11720125 (Pubitemid 33043139)
109. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Hampton TG, Stasko MR, Kale A, Amende I, Costa AC, Physiol Behav 2004 82 381 389 10.1016/j.physbeh.2004.04.006 15276802 (Pubitemid 38981625)
110. Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. Vidal V, García S, Martínez P, Corrales A, Flórez J, Rueda N, Sharma A, Martínez-Cué C, Neuroscience 2012 220 158 168 22728103
111. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down Syndrome: activation of b1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, et al. Neurobiol Dis 2011 43 397 413 10.1016/j.nbd.2011.04.011 21527343
112. Motor learning in Ts65Dn mice, a model for Down syndrome. Hyde LA, Crnic LS, Pollock A, Bickford PC, Dev Psychobiol 2001 38 33 45 10.1002/1098-2302(2001) 38:1<33::AID-DEV3>3.0.CO;2-0 11150059 (Pubitemid 32037354)
113. Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (Ts65Dn) mice. Klein SL, Kriegsfeld LJ, Hairston JE, Rau V, Nelson RJ, Yarowsky PJ, Physiol Behav 1996 60 1159 1164 10.1016/0031-9384(96)00218-1 8884947 (Pubitemid 26336736)
114. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Escorihuela RM, Fernandez-Teruel A, Vallina IF, Baamonde C, Lumbreras MA, Dierssen M, Tobena A, Florez J, Neurosci Lett 1995 199 143 146 10.1016/0304-3940(95)12052-6 8584244
115. A mouse model for Down syndrome exhibits learning and behaviour deficits. Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT, Nat Genet 1995 11 177 184 10.1038/ng1095-177 7550346
116. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML, Biotechniques 2000 29 52 54 10907076 (Pubitemid 30439416)
117. Quantitative PCR genotyping assay for the Ts65Dn mouse model of Down syndrome. Liu DP, Schmidt C, Billings T, Davisson MT, Biotechniques 2003 35 1170 1174 1176, 1178 14682051
118. Axonal GABAA receptors increase cerebellar granule cell excitability and synaptic activity. Pugh JR, Jahr CE, J Neurosci 2011 31 565 574 10.1523/JNEUROSCI.4506-10.2011 21228165
119. Maturation of EPSCs and intrinsic membrane properties enhances precision at a cerebellar synapse. Cathala L, Brickley S, Cull-Candy S, Farrant M, J Neurosci 2003 23 6074 6085 12853426 (Pubitemid 36859445)
120. TASK-3 two-pore domain potassium channels enable sustained high-frequency firing in cerebellar granule neurons. Brickley SG, Aller MI, Sandu C, Veale EL, Alder FG, Sambi H, Mathie A, Wisden W, J Neurosci 2007 27 9329 9340 10.1523/JNEUROSCI.1427-07.2007 17728447 (Pubitemid 47358198)
121. Persistent Nav1.6 current at axon initial segments tunes spike timing of cerebellar granule cells. Osorio N, Cathala L, Meisler MH, Crest M, Magistretti J, Delmas P, J Physiol 2010 588 651 670 20173079
122. Synaptic excitation of individual rat cerebellar granule cells in situ: evidence for the role of NMDA receptors. D'Angelo E, De Filippi G, Rossi P, Taglietti V, J Physiol 1995 484 397 413 7602534
123. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. Glykys J, Mody I, J Physiol 2007 582 1163 1178 10.1113/jphysiol.2007.134460 17525114 (Pubitemid 47104346)
124. Bean BP: The action potential in mammalian central neurons. Nat Rev Neurosci 2007, 8:451-465.